論文

国際誌
2020年12月

Serum anti-LRPAP1 is a common biomarker for digestive organ cancers and atherosclerotic diseases.

Cancer science
  • Makoto Sumazaki
  • Hideaki Shimada
  • Masaaki Ito
  • Fumiaki Shiratori
  • Eiichi Kobayashi
  • Yoichi Yoshida
  • Akihiko Adachi
  • Tomoo Matsutani
  • Yasuo Iwadate
  • Seiichiro Mine
  • Toshio Machida
  • Ikuo Kamitsukasa
  • Masahiro Mori
  • Kazuo Sugimoto
  • Akiyuki Uzawa
  • Satoshi Kuwabara
  • Yoshio Kobayashi
  • Mikiko Ohno
  • Eiichiro Nishi
  • Yoshiro Maezawa
  • Minoru Takemoto
  • Koutaro Yokote
  • Hirotaka Takizawa
  • Koichi Kashiwado
  • Hideo Shin
  • Takashi Kishimoto
  • Kazuyuki Matsushita
  • Sohei Kobayashi
  • Rika Nakamura
  • Natsuko Shinmen
  • Hideyuki Kuroda
  • Xiao-Meng Zhang
  • Hao Wang
  • Ken-Ichiro Goto
  • Takaki Hiwasa
  • 全て表示

111
12
開始ページ
4453
終了ページ
4464
記述言語
英語
掲載種別
研究論文(学術雑誌)
DOI
10.1111/cas.14652

Some cancers are related to atherosclerotic diseases; therefore, these two types of disease may share some antibody biomarkers in common. To investigate this, a first screening of sera was performed from patients with esophageal squamous cell carcinoma (ESCC) or acute ischemic stroke (AIS) for serological identification of antigens using recombinant cDNA expression cloning (SEREX). The amplified luminescent proximity homogeneous assay-linked immunosorbent assay (AlphaLISA) method, which incorporates glutathione donor beads and anti-human IgG acceptor beads, was used to evaluate serum antibody levels. SEREX screening identified low-density lipoprotein receptor-related protein-associated protein 1 (LRPAP1) as a target antigen of serum IgG antibodies in the sera of patients with ESCC or AIS. Antigens, including recombinant glutathione S-transferase-fused LRPAP1 protein, were prepared to examine serum antibody levels. AlphaLISA revealed significantly higher antibody levels against the LRPAP1 protein in patients with solid cancers such as ESCC and colorectal carcinoma and some atherosclerosis-related diseases such as AIS and diabetes mellitus compared with healthy donors. Correlation analysis revealed that the elevated serum antibody levels against LRPAP1 were associated with smoking, a well-known risk factor for both cancer and atherosclerosis. Serum LRPAP1 antibody is therefore a common marker for the early diagnosis of some cancers and atherosclerotic diseases and may reflect diseases caused by habitual smoking.

リンク情報
DOI
https://doi.org/10.1111/cas.14652
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/32939876
PubMed Central
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7734161
ID情報
  • DOI : 10.1111/cas.14652
  • PubMed ID : 32939876
  • PubMed Central 記事ID : PMC7734161

エクスポート
BibTeX RIS